Thursday, 16 October 2014

NovaLead Pharma Pvt. Ltd. - Product Pipeline Review - 2014

NovaLead Pharma Pvt. Ltd. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides comprehensive information on the current therapeutic developmental pipeline of NovaLead Pharma Pvt. Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of NovaLead Pharma Pvt. Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NovaLead Pharma Pvt. Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the NovaLead Pharma Pvt. Ltd.’s pipeline products

Reasons to buy

- Evaluate NovaLead Pharma Pvt. Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NovaLead Pharma Pvt. Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NovaLead Pharma Pvt. Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NovaLead Pharma Pvt. Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NovaLead Pharma Pvt. Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of NovaLead Pharma Pvt. Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit NovaLead Pharma Pvt. Ltd. - Product Pipeline Review - 2014

Heptares Therapeutics Ltd. - Product Pipeline Review - 2014

Heptares Therapeutics Ltd. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides comprehensive information on the current therapeutic developmental pipeline of Heptares Therapeutics Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Heptares Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Heptares Therapeutics Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Heptares Therapeutics Ltd.’s pipeline products

Reasons to buy

- Evaluate Heptares Therapeutics Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Heptares Therapeutics Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Heptares Therapeutics Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Heptares Therapeutics Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Heptares Therapeutics Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Heptares Therapeutics Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Heptares Therapeutics Ltd. - Product Pipeline Review - 2014

AlphaVax, Inc. - Product Pipeline Review - 2014

AlphaVax, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides comprehensive information on the current therapeutic developmental pipeline of AlphaVax, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of AlphaVax, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AlphaVax, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the AlphaVax, Inc.’s pipeline products

Reasons to buy

- Evaluate AlphaVax, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AlphaVax, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AlphaVax, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AlphaVax, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AlphaVax, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AlphaVax, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit AlphaVax, Inc. - Product Pipeline Review - 2014

Lentigen Corporation - Product Pipeline Review - 2014

Lentigen Corporation - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides comprehensive information on the current therapeutic developmental pipeline of Lentigen Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Lentigen Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lentigen Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Lentigen Corporation’s pipeline products

Reasons to buy

- Evaluate Lentigen Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lentigen Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lentigen Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lentigen Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lentigen Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Lentigen Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Lentigen Corporation - Product Pipeline Review - 2014

Microbiotix, Inc. - Product Pipeline Review - 2014

Microbiotix, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides comprehensive information on the current therapeutic developmental pipeline of Microbiotix, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Microbiotix, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Microbiotix, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Microbiotix, Inc.’s pipeline products

Reasons to buy

- Evaluate Microbiotix, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Microbiotix, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Microbiotix, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Microbiotix, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Microbiotix, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Microbiotix, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Microbiotix, Inc. - Product Pipeline Review - 2014

PharmAbcine, Inc. - Product Pipeline Review - 2014

PharmAbcine, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides comprehensive information on the current therapeutic developmental pipeline of PharmAbcine, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of PharmAbcine, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of PharmAbcine, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the PharmAbcine, Inc.’s pipeline products

Reasons to buy

- Evaluate PharmAbcine, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of PharmAbcine, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the PharmAbcine, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of PharmAbcine, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of PharmAbcine, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of PharmAbcine, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit PharmAbcine, Inc. - Product Pipeline Review - 2014

Theraclone Sciences, Inc. - Product Pipeline Review - 2014

Theraclone Sciences, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides comprehensive information on the current therapeutic developmental pipeline of Theraclone Sciences, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Theraclone Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Theraclone Sciences, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Theraclone Sciences, Inc.’s pipeline products

Reasons to buy

- Evaluate Theraclone Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Theraclone Sciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Theraclone Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Theraclone Sciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Theraclone Sciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Theraclone Sciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Theraclone Sciences, Inc. - Product Pipeline Review - 2014